Canada (CA)

Long-Term (156-Week) Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Pooled Safety Analysis of 3 Phase III, Randomized, Controlled Trials (2016) Mease PJ, Gladman DD, Gomez-Reino JJ, Hall S, Kavanaugh A, Lespessailles E, Schett G, et al. Conference contribution Apremilast Treatment and Long-Term (156-Week) Improvements in Enthesitis and Dactylitis in Patients with Psoriatic Arthritis: Pooled Analysis of a Large Database of 3 Phase III, Randomized, Controlled Trials (2016) Gladman DD, Kavanaugh A, Gomez-Reino JJ, Wollenhaupt J, Cutolo M, Schett G, Lespessailles E, et al. Conference contribution APREMILAST, AN ORAL PHOSPHODIESTERASE-4 INHIBITOR, IS ASSOCIATED WITH LONG-TERM (104-WEEK) IMPROVEMENTS IN ENTHESITIS AND DACTYLITIS IN PATIENTS WITH PSORIATIC ARTHRITIS: POOLED RESULTS FROM THREE PHASE III RANDOMIZED CONTROLLED TRIALS (2016) Gladman DD, Kavanaugh A, Adebajo AO, Gomez-Reino JJ, Wollenhaupt J, Cutolo M, Schett G, et al. Conference contribution Apremilast, an Oral Phosphodiesterase 4 Inhibitor, is Associated with Long-term (104-Week) Improvements in Enthesitis and Dactylitis in Patients with Psoriatic Arthritis: Pooled Results from Three Phase III, Randomized, Controlled Trials (2016) Gladman D, Kavanaugh A, Adebajo A, Gomez-Reino J, Wollenhaupt J, Cutolo M, Schett G, et al. Conference contribution THE EUROPEAN SOCIAL PREFERENCE MEASUREMENT (ESPM) STUDY: CONCEPTUAL CONSIDERATIONS AND IMPLEMENTATION (2016) Schlander M, Telser H, Holm S, Marshall DA, Nord E, Richardson J, Garattini S, et al. Conference contribution Comparison between core-lab and site-read assessment of coronary CT angiography for detection of ischemia-causing lesions: a substudy of the NXT trial (2016) Marwan M, Gaur S, Leipsic J, Seneviratne S, Ito H, Mauri L, De Bruyne B, et al. Conference contribution The ratio of coronary arterial lumen volume to left ventricle mass identifies patients with nonobstructive coronary artery disease having vessel-specific ischemia measured by fractional flow reserve (2016) Taylor C, Gaur S, Khem S, Kim HJ, Wilk A, Zarins CK, Achenbach S, et al. Conference contribution Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (2016) Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann J, Nauck MA, Nissen SE, et al. Journal article Population-Attributable Fractions of Modifiable Lifestyle Factors for CKD and Mortality in Individuals With Type 2 Diabetes: A Cohort Study (2016) Dunkler D, Kohl M, Teo KK, Heinze G, Dehghan M, Clase CM, Gao P, et al. Journal article Coronary plaque quantification and fractional flow reserve by coronary computed tomography angiography identify ischaemia-causing lesions (2016) Gaur S, Ovrehus KA, Dey D, Leipsic J, Botker HE, Jensen JM, Narula J, et al. Journal article